发明名称 |
Extracts from kibdelos porangium as antibacterial agents |
摘要 |
The present invention relates to novel compounds of formulae (I) and (II) and pharmaceutically acceptable salts thereof that are useful in the treatment and/or prevention of human and animal bacterial infections and associated diseases and conditions; compositions containing such compounds; derivation of such compounds by fermentation and isolation, partial synthesis and total synthesis; methods of inhibiting bacterial growth; methods of treating, preventing or controlling bacterial infection; biologically pure cultures of bacterial strains from which such compounds may be produced; and processes for preparing compositions containing such compounds.; |
申请公布号 |
US9126983(B2) |
申请公布日期 |
2015.09.08 |
申请号 |
US201013518613 |
申请日期 |
2010.12.17 |
申请人 |
Merck Sharp & Dohme Corp.;Merck Sharp & Dohme de Espana SA |
发明人 |
Singh Sheo;Polishook Jon D.;Zink Deborah L.;Genilloud Olga;Goetz Michael;Vicente Francisca;Olsen David Brian;Smith Scott Knoble |
分类号 |
C07H15/26;A61P31/04;A61K31/706;A61K31/7056;A01N43/86;A01N43/36;C07D407/14;A61K31/535;A61K31/4025;C07D413/14;C12P17/16;C12R1/01 |
主分类号 |
C07H15/26 |
代理机构 |
|
代理人 |
Ginkel Laura M.;Lake Julie M. |
主权项 |
1. A method of inhibiting growth of bacteria, the method comprising treating Clostridium difficile with an effective amour of one or more purified compounds selected from compounds of formula I and formula II: and pharmaceutically acceptable salts thereof,wherein:
R1 and R2 are independently selected from the group consisting of hydrogen and halogen; and R3 selected from the group consisting of hydrogen and C1-C6 alkyl; and and pharmaceutically acceptable salts thereof, wherein: R1 and R2 are independently selected from the group consisting of hydrogen and halogen; and R3 is hydrogen. |
地址 |
Rahway NJ US |